NexCap 40 mg (Capsule (Enteric Coated))
Unit Price: ৳ 10.00 (3 x 10: ৳ 300.00)
Strip Price: ৳ 100.00
Medicine Details
Category | Details |
---|---|
Generic | Esomeprazole |
Company | Unimed unihealth pharmaceuticals ltd |
Also available as |
Indications
- Relief from chronic heartburn symptoms and other symptoms associated with GERD
- Healing of erosive esophagitis
- Maintenance of healing of erosive esophagitis
- Eradication of Helicobacter pylori infection in patients with duodenal ulcer disease
- Zollinger-Ellison Syndrome
- Acid-related Dyspepsia
- Duodenal & Gastric ulcer
Pharmacology
- Proton pump inhibitor
- Suppresses gastric acid secretion
- Inhibition of the H+/K+-ATPase in the gastric parietal cell
- Enteric-coated pellet formulation
- Peak plasma levels occur at approximately 1.5 hours
- Systemic bioavailability is approximately 90%
- Extensively metabolized in the liver
- CYP2C19 and CYP3A4 dependent metabolism
- Plasma elimination half-life is approximately 1–1.5 hours
Dosage
- Healing of Erosive Esophagitis: 20 mg or 40 mg Once Daily for 4-8 Weeks
- Maintenance of Healing of Erosive Esophagitis: 20 mg Once Daily
- Symptomatic GERD: 20 mg Once Daily for 4 Weeks
- Helicobacter Pylori eradication: Triple Therapy for 10 days
- Zollinger-Ellison Syndrome: 20-80 mg once daily
- Acid-related Dyspepsia: 20-40 mg once daily for 2-4 weeks
- Duodenal ulcer: 20 mg once daily for 2-4 weeks
- Gastric ulcer: 20-40 mg once daily for 4-8 weeks
- IV Injection: 20 mg or 40 mg once daily, with specific administration times for different age groups and conditions
Administration
- Tablet or capsule: Swallowed whole and taken one hour before a meal
- Oral Suspension: Should be taken with water and administered through a nasogastric or gastric tube if necessary
- IV Injection: Must be administered intravenously over a period of at least 3 minutes
Interaction
- Metabolized in the liver by CYP2C19 and CYP3A4
- Not likely to inhibit specific CYP enzymes
- May potentially interfere with CYP2C19
- Inhibits gastric acid secretion, potentially interfering with the absorption of other drugs
Contraindications
- Known hypersensitivity to any of the formulation
Side Effects
- Headache
- Diarrhoea
- Nausea
- Flatulence
- Abdominal pain
- Constipation
- Dry mouth
Pregnancy & Lactation
- No adequate and well-controlled studies in pregnant women
- Animal studies have revealed no teratogenic effects
- Excretion in milk not studied, breastfeeding should be discontinued if essential
Precautions & Warnings
- Symptomatic response to therapy does not preclude the presence of gastric malignancy
- NexCap capsules should be taken at least one hour before meals
- Use with caution for patients who have difficulty swallowing capsules
Use in Special Populations
- Paediatric Use: Safety and effectiveness not established
- Geriatric Use: No overall differences in safety and efficacy observed
- Hepatic Insufficiency: No dosage adjustment for mild to moderate hepatic insufficiency
- Renal Insufficiency: Pharmacokinetics not expected to be altered
Overdose Effects
- Lethal to rats at high doses
- Reduced motor activity, changes in respiratory frequency, tremor, ataxia, and intermittent clonic convulsions
Storage Conditions
- Store at a temperature not exceeding 30°C
- Protect from light and moisture
- Keep out of reach of children
Chemical Structure
- Molecular Formula: C17H19N3O3S
Common Questions about NexCap 40 mg Capsule
- Multiple uses including treating heartburn, GERD, ulcers, and preventing erosive esophagitis recurrence
- Common side effects include headaches, diarrhea, nausea, and more
- No adverse effects on pregnancy or breastfeeding reported
- Rapid onset of action within a few hours
Related Brands
- Nexe 20 mg (Tablet (Enteric Coated)) - apex-pharmaceuticals-ltd
- Nexe 40 mg (Capsule (Enteric Coated)) - apex-pharmaceuticals-ltd
- Nexum 20 mg (Capsule (Enteric Coated)) - square-pharmaceuticals-plc
- Nexum 40 mg (Capsule (Enteric Coated)) - square-pharmaceuticals-plc
- Nexum 40 mg/vial (IV Injection) - square-pharmaceuticals-plc